Leonie I. Kroeze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leonie I. Kroeze has a total of 326 co-authors. Here are the top co-authors by number of shared publications:
Joop H. Jansen
Laboratory of Hematology and
8 shared publications- Patricia J. T. A. Groenen
Department of Pathology Radboud university medical center Nijmegen The Netherlands
7 shared publications - Marjolijn J. L. Ligtenberg
Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
6 shared publications Bert A. van der Reijden
Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands
5 shared publicationsTheresia N. Koorenhof-Scheele
Laboratory of Hematology and
5 shared publications- Joop H. Jansen
Department of Laboratory Medicine, Laboratory of Hematology Radboud University Medical Center Nijmegen The Netherlands
4 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 248, 117060
Tumour-first DNA testing as a gateway to germline screening in patients with metastatic prostate cancer
- 19 September 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 248, 117060
Open AccessTumour-first DNA testing as a gateway to germline screening in patients with metastatic prostate cancer
- Open Access
- 31 October 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 134 (2) , 306-316
Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study
Background Precision oncology using genotype-matched treatments (GMT) offers potential to improve survival in metastatic castration-resistant prostate cancer (mCRPC). Patient and methods In the PROMPT study (NCT04746300), reflex tumour testing through next-generation sequencing was performed in treatment-naïve or first-line mCRPC patients. All patients received a molecular tumour board (MTB) recommendation for GMT based on predefined druggable targets (DT). The main objective was to identify clinicopathological variables associated with DT. Results Analysis included 340 tissue samples from 307 patients, 51% of samples were newly biopsied. Valid results were generated in 84% (76% new, 92% archived; P < 0.01). DT were identified in 39% of the patients, with PI3K-AKT (26%) and Homologous Recombination (HR; 21%) pathways most frequently affected. Metastatic tissue, especially from mCRPC setting (P < 0.01), yielded higher GMT recommendations than primary tissue (P = 0.03). HR-associated genes were linked with shorter ADT-to-CRPC time (OR 3.77, 95%CI 1.62–10.32, P < 0.01). PI3K-AKT alterations were associated with metachronous metastatic disease (OR 0.48, 95%CI 0.26–0.89, P = 0.021) and longer time to CRPC (OR 0.47, 95%CI 0.25–0.87, P = 0.017). No distinct variables predicted DT genotypes. Conclusion Molecular tumour testing should preferably be done on metastatic mCRPC tissue. No combination of features could robustly identify druggable genotypes; therefore, reflex molecular characterisation should be routine for every mCRPC patient.
- 31 October 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 134 (2) , 306-316
Open AccessMolecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study
Background Precision oncology using genotype-matched treatments (GMT) offers potential to improve survival in metastatic castration-resistant prostate cancer (mCRPC). Patient and methods In the PROMPT study (NCT04746300), reflex tumour testing through next-generation sequencing was performed in treatment-naïve or first-line mCRPC patients. All patients received a molecular tumour board (MTB) recommendation for GMT based on predefined druggable targets (DT). The main objective was to identify clinicopathological variables associated with DT. Results Analysis included 340 tissue samples from 307 patients, 51% of samples were newly biopsied. Valid results were generated in 84% (76% new, 92% archived; P < 0.01). DT were identified in 39% of the patients, with PI3K-AKT (26%) and Homologous Recombination (HR; 21%) pathways most frequently affected. Metastatic tissue, especially from mCRPC setting (P < 0.01), yielded higher GMT recommendations than primary tissue (P = 0.03). HR-associated genes were linked with shorter ADT-to-CRPC time (OR 3.77, 95%CI 1.62–10.32, P < 0.01). PI3K-AKT alterations were associated with metachronous metastatic disease (OR 0.48, 95%CI 0.26–0.89, P = 0.021) and longer time to CRPC (OR 0.47, 95%CI 0.25–0.87, P = 0.017). No distinct variables predicted DT genotypes. Conclusion Molecular tumour testing should preferably be done on metastatic mCRPC tissue. No combination of features could robustly identify druggable genotypes; therefore, reflex molecular characterisation should be routine for every mCRPC patient.
- Open Access
- 13 October 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (13) , 2504-2517
Challenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factors
Follicular lymphoma (FL) exhibits considerable heterogeneity in clinical trajectories and molecular characteristics. This study assessed the association between clinical presentation, histopathological findings, and mutational profiles with the duration of a Watch-and-Wait (WW) strategy in a cohort of 124 FL patients managed with a WW approach at diagnosis. Median event-free survival (EFS) (time to treatment or death) was 29 months. Hemoglobin below B2M mutations and high m7-FLIPI score correlated with inferior EFS, though present in only 4% and 15% of cases, respectively. WW patients were compared to 91 patients receiving upfront immunochemotherapy to evaluate the differences in prognostic factors and mutational profiles. Despite distinct clinical prognostic factors, mutational profiles were comparable between the two groups, even at clinical extremes. These findings underscore the challenges in predicting the duration of a WW approach.
- 13 October 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (13) , 2504-2517
Open AccessChallenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factors
Follicular lymphoma (FL) exhibits considerable heterogeneity in clinical trajectories and molecular characteristics. This study assessed the association between clinical presentation, histopathological findings, and mutational profiles with the duration of a Watch-and-Wait (WW) strategy in a cohort of 124 FL patients managed with a WW approach at diagnosis. Median event-free survival (EFS) (time to treatment or death) was 29 months. Hemoglobin below B2M mutations and high m7-FLIPI score correlated with inferior EFS, though present in only 4% and 15% of cases, respectively. WW patients were compared to 91 patients receiving upfront immunochemotherapy to evaluate the differences in prognostic factors and mutational profiles. Despite distinct clinical prognostic factors, mutational profiles were comparable between the two groups, even at clinical extremes. These findings underscore the challenges in predicting the duration of a WW approach.
- Open Access
- 9 October 2025
- Published by Springer Nature in Journal of Hematopathology
- Vol. 18 (1) , 1-9
Analysis of myeloid neoplasms with isolated trisomy 19 reveals a novel MDS subgroup characterized by the presence of ring sideroblasts, fibrosis and SRSF2 and/or ASXL1 mutations
We collected 97 cases of myeloid neoplasia with the rare cytogenetic event of isolated trisomy 19 (+19), with the aim to characterize this group clinically and pathologically. 51 patients with myelodysplastic syndrome (MDS +19) and 11 patients with myelodysplastic/myeloproliferative neoplasms (MDS/MPN +19) presented with +19 at disease onset and were further analyzed. Patients with insufficient data were excluded. We collected additional clinical and laboratory data and performed mutation analysis on available bone marrow biopsies. The 62 patients of both disease groups turned out to be remarkably homogeneous in terms of male sex (85%), the presence of anemia with increased numbers of ring sideroblasts (RS, 80%), the absence of an SF3B1 mutation (95%), and the overall rather consistent presence of SRSF2 (61%) or ASXL1 (39%) mutations. MDS +19 patients with available follow-up (1 month to 7.5 years) presented or progressed with significant fibrosis (45%), leuko- or monocytosis (13%) or acute leukemia (28%). Compared to a control cohort of 23 patients with MDS and an SRSF2 mutation, but without isolated +19 (MDS-SRSF2), the 16 MDS +19 patients with SRSF2 mutation and the 12 MDS +19 patients with an ASXL1 mutation showed a striking difference in the presence of ≥ 15% RS (73% and 67% versus 17% in MDS-SRSF2) and the occurrence of fibrosis (44% and 57% versus 4% in MDS-SRSF2). Although all individual features observed in the MDS +19 and MDS/MPN +19 cohorts are seen in MDS and MDS/MPN in general, their combination is rather unique and provides clues regarding disease evolution in this rare, cytogenetically defined group of myeloid neoplasia.
- 9 October 2025
- Published by Springer Nature in Journal of Hematopathology
- Vol. 18 (1) , 1-9
Open AccessAnalysis of myeloid neoplasms with isolated trisomy 19 reveals a novel MDS subgroup characterized by the presence of ring sideroblasts, fibrosis and SRSF2 and/or ASXL1 mutations
We collected 97 cases of myeloid neoplasia with the rare cytogenetic event of isolated trisomy 19 (+19), with the aim to characterize this group clinically and pathologically. 51 patients with myelodysplastic syndrome (MDS +19) and 11 patients with myelodysplastic/myeloproliferative neoplasms (MDS/MPN +19) presented with +19 at disease onset and were further analyzed. Patients with insufficient data were excluded. We collected additional clinical and laboratory data and performed mutation analysis on available bone marrow biopsies. The 62 patients of both disease groups turned out to be remarkably homogeneous in terms of male sex (85%), the presence of anemia with increased numbers of ring sideroblasts (RS, 80%), the absence of an SF3B1 mutation (95%), and the overall rather consistent presence of SRSF2 (61%) or ASXL1 (39%) mutations. MDS +19 patients with available follow-up (1 month to 7.5 years) presented or progressed with significant fibrosis (45%), leuko- or monocytosis (13%) or acute leukemia (28%). Compared to a control cohort of 23 patients with MDS and an SRSF2 mutation, but without isolated +19 (MDS-SRSF2), the 16 MDS +19 patients with SRSF2 mutation and the 12 MDS +19 patients with an ASXL1 mutation showed a striking difference in the presence of ≥ 15% RS (73% and 67% versus 17% in MDS-SRSF2) and the occurrence of fibrosis (44% and 57% versus 4% in MDS-SRSF2). Although all individual features observed in the MDS +19 and MDS/MPN +19 cohorts are seen in MDS and MDS/MPN in general, their combination is rather unique and provides clues regarding disease evolution in this rare, cytogenetically defined group of myeloid neoplasia.
- 24 September 2025
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 27 (12) , 1154-1165
Next-Generation Sequencing–Based T-Cell Receptor Gene Rearrangement Analysis in Nodal T Follicular Helper Cell Lymphoma, a Comparison with the EuroClonality/BIOMED-2 Assay
- 24 September 2025
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 27 (12) , 1154-1165
Next-Generation Sequencing–Based T-Cell Receptor Gene Rearrangement Analysis in Nodal T Follicular Helper Cell Lymphoma, a Comparison with the EuroClonality/BIOMED-2 Assay
- Open Access
- 21 January 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (5)
Multimodal integration of blood RNA and ctDNA reflects response to immunotherapy in metastatic urothelial cancer
BACKGROUND. Previously, we demonstrated that changes in circulating tumor DNA (ctDNA) are promising biomarkers for early response prediction (ERP) to immune checkpoint inhibitors (ICIs) in metastatic urothelial cancer (mUC). In this study, we investigated the value of whole-blood immunotranscriptomics for ERP-ICI and integrated both biomarkers into a multimodal model to boost accuracy. METHODS. Blood samples of 93 patients were collected at baseline and after 2–6 weeks of ICI for ctDNA ( n = 88) and immunotranscriptome ( n = 79) analyses. ctDNA changes were dichotomized into increase or no increase, the latter including patients with undetectable ctDNA. For RNA model development, the cohort was split into discovery ( n = 29), test ( n = 29), and validation sets ( n = 21). Finally, RNA- and ctDNA-based predictions were integrated in a multimodal model. Clinical benefit (CB) was defined as progression-free survival beyond 6 months. RESULTS. Sensitivity (SN) and specificity (SP) of ctDNA increase for predicting non-CB (N-CB) was 59% and 92%, respectively. Immunotranscriptome analysis revealed upregulation of T cell activation, proliferation, and interferon signaling during treatment in the CB group, in contrast with N-CB patients. Based on these differences, a 10-gene RNA model was generated, reaching an SN and SP of 73% and 79%, respectively, in the test and 67% and 67% in the validation set for predicting N-CB. Multimodal model integration led to superior performance, with an SN and SP of 79% and 100%, respectively, in the validation cohort. CONCLUSION. The combination of whole-blood immunotranscriptome and ctDNA in a multimodal model showed promise for ERP-ICI in mUC and accurately identified patients with N-CB. FUNDING. Eurostars grant E! 114908 - PRECISE, Paul Speth Foundation (Bullseye project).
- 21 January 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (5)
Open AccessMultimodal integration of blood RNA and ctDNA reflects response to immunotherapy in metastatic urothelial cancer
BACKGROUND. Previously, we demonstrated that changes in circulating tumor DNA (ctDNA) are promising biomarkers for early response prediction (ERP) to immune checkpoint inhibitors (ICIs) in metastatic urothelial cancer (mUC). In this study, we investigated the value of whole-blood immunotranscriptomics for ERP-ICI and integrated both biomarkers into a multimodal model to boost accuracy. METHODS. Blood samples of 93 patients were collected at baseline and after 2–6 weeks of ICI for ctDNA ( n = 88) and immunotranscriptome ( n = 79) analyses. ctDNA changes were dichotomized into increase or no increase, the latter including patients with undetectable ctDNA. For RNA model development, the cohort was split into discovery ( n = 29), test ( n = 29), and validation sets ( n = 21). Finally, RNA- and ctDNA-based predictions were integrated in a multimodal model. Clinical benefit (CB) was defined as progression-free survival beyond 6 months. RESULTS. Sensitivity (SN) and specificity (SP) of ctDNA increase for predicting non-CB (N-CB) was 59% and 92%, respectively. Immunotranscriptome analysis revealed upregulation of T cell activation, proliferation, and interferon signaling during treatment in the CB group, in contrast with N-CB patients. Based on these differences, a 10-gene RNA model was generated, reaching an SN and SP of 73% and 79%, respectively, in the test and 67% and 67% in the validation set for predicting N-CB. Multimodal model integration led to superior performance, with an SN and SP of 79% and 100%, respectively, in the validation cohort. CONCLUSION. The combination of whole-blood immunotranscriptome and ctDNA in a multimodal model showed promise for ERP-ICI in mUC and accurately identified patients with N-CB. FUNDING. Eurostars grant E! 114908 - PRECISE, Paul Speth Foundation (Bullseye project).
- Open Access
- 29 September 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (19) , 5911-5924
A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
Despite high cure rates in classic Hodgkin lymphoma (cHL), relapses are observed. Whether relapsed cHL represents second primary lymphoma or an underlying T-cell lymphoma (TCL) mimicking cHL is underinvestigated. To analyze the nature of cHL recurrences, in-depth clonality testing of immunoglobulin (Ig) and T-cell receptor (TCR) rearrangements was performed in paired cHL diagnoses and recurrences among 60 patients, supported by targeted mutation analysis of lymphoma-associated genes. Clonal Ig rearrangements were detected by next-generation sequencing (NGS) in 69 of 120 (58%) diagnoses and recurrence samples. The clonal relationship could be established in 34 cases, identifying clonally related relapsed cHL in 24 of 34 patients (71%). Clonally unrelated cHL was observed in 10 of 34 patients (29%) as determined by IG-NGS clonality assessment and confirmed by the identification of predominantly mutually exclusive gene mutations in the paired cHL samples. In recurrences of >2 years, ∼60% of patients with cHL for whom the clonal relationship could be established showed a second primary cHL. Clonal TCR gene rearrangements were identified in 14 of 125 samples (11%), and TCL-associated gene mutations were detected in 7 of 14 samples. Retrospective pathology review with integration of the molecular findings were consistent with an underlying TCL in 5 patients aged >50 years. This study shows that cHL recurrences, especially after 2 years, sometimes represent a new primary cHL or TCL mimicking cHL, as uncovered by NGS-based Ig/TCR clonality testing and gene mutation analysis. Given the significant therapeutic consequences, molecular testing of a presumed relapse in cHL is crucial for subsequent appropriate treatment strategies adapted to the specific lymphoma presentation.
- 29 September 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (19) , 5911-5924
Open AccessA significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
Despite high cure rates in classic Hodgkin lymphoma (cHL), relapses are observed. Whether relapsed cHL represents second primary lymphoma or an underlying T-cell lymphoma (TCL) mimicking cHL is underinvestigated. To analyze the nature of cHL recurrences, in-depth clonality testing of immunoglobulin (Ig) and T-cell receptor (TCR) rearrangements was performed in paired cHL diagnoses and recurrences among 60 patients, supported by targeted mutation analysis of lymphoma-associated genes. Clonal Ig rearrangements were detected by next-generation sequencing (NGS) in 69 of 120 (58%) diagnoses and recurrence samples. The clonal relationship could be established in 34 cases, identifying clonally related relapsed cHL in 24 of 34 patients (71%). Clonally unrelated cHL was observed in 10 of 34 patients (29%) as determined by IG-NGS clonality assessment and confirmed by the identification of predominantly mutually exclusive gene mutations in the paired cHL samples. In recurrences of >2 years, ∼60% of patients with cHL for whom the clonal relationship could be established showed a second primary cHL. Clonal TCR gene rearrangements were identified in 14 of 125 samples (11%), and TCL-associated gene mutations were detected in 7 of 14 samples. Retrospective pathology review with integration of the molecular findings were consistent with an underlying TCL in 5 patients aged >50 years. This study shows that cHL recurrences, especially after 2 years, sometimes represent a new primary cHL or TCL mimicking cHL, as uncovered by NGS-based Ig/TCR clonality testing and gene mutation analysis. Given the significant therapeutic consequences, molecular testing of a presumed relapse in cHL is crucial for subsequent appropriate treatment strategies adapted to the specific lymphoma presentation.
- Open Access
- 17 July 2023
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (10) , 729-739
EuroClonality-NGS Recommendations for Evaluation of B-Cell Clonality Analysis by Next-Generation Sequencing
- 17 July 2023
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (10) , 729-739
Open AccessEuroClonality-NGS Recommendations for Evaluation of B-Cell Clonality Analysis by Next-Generation Sequencing
- Open Access
Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
Patients with metastatic castration-resistant prostate cancer (mCRPC) harbouring homologous recombination repair-related gene aberrations (HRRm) can derive meaningful benefits from both platinum-based chemotherapy (PlCh) and PARP inhibitors (PARPi). Cross-resistance between these agents is well-recognised in other tumour types but data on prostate cancer is lacking. In this retrospective pre-planned study, we assessed 28 HRRm mCRPC patients who received PlCh and PARPi. Progression-free survival (PFS) on initial therapy was longer than on subsequent therapy (median 5.3 vs. 3.4 months, p = 0.016). The median PFS of PlCh was influenced by the order of agents, with 3.6 months shorter PFS after PARPi than when administered first. The median PFS of PARPi was less influenced, with 0.9 months shorter PFS after PlCh than before. In the PARPi-first subgroup, six out of 16 evaluable patients (37.5%) had a >50% PSA decline to PlCh, and two of eight (25.0%) had a radiographic response to PlCh. In the PlCh-first subgroup, 6/10 (60.0%) had a >50% PSA decline, and 5/9 (55.6%) had a radiographic response to PARPi. These data show >40% of the cohort is sensitive to a subsequent HRR-targeting agent. PlCh appears to induce less cross-resistance than PARPi. Additional data on resistance mechanisms will be crucial in defining an optimal treatment sequence in HRRm mCRPC patients.
Open AccessCross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
Patients with metastatic castration-resistant prostate cancer (mCRPC) harbouring homologous recombination repair-related gene aberrations (HRRm) can derive meaningful benefits from both platinum-based chemotherapy (PlCh) and PARP inhibitors (PARPi). Cross-resistance between these agents is well-recognised in other tumour types but data on prostate cancer is lacking. In this retrospective pre-planned study, we assessed 28 HRRm mCRPC patients who received PlCh and PARPi. Progression-free survival (PFS) on initial therapy was longer than on subsequent therapy (median 5.3 vs. 3.4 months, p = 0.016). The median PFS of PlCh was influenced by the order of agents, with 3.6 months shorter PFS after PARPi than when administered first. The median PFS of PARPi was less influenced, with 0.9 months shorter PFS after PlCh than before. In the PARPi-first subgroup, six out of 16 evaluable patients (37.5%) had a >50% PSA decline to PlCh, and two of eight (25.0%) had a radiographic response to PlCh. In the PlCh-first subgroup, 6/10 (60.0%) had a >50% PSA decline, and 5/9 (55.6%) had a radiographic response to PARPi. These data show >40% of the cohort is sensitive to a subsequent HRR-targeting agent. PlCh appears to induce less cross-resistance than PARPi. Additional data on resistance mechanisms will be crucial in defining an optimal treatment sequence in HRRm mCRPC patients.
- Open Access
Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma Subgroups
Angiosarcomas (AS) are extremely rare and aggressive vascular malignancies subdivided in de novo primary AS (pAS) and secondary AS (sAS). We hypothesize that the combination of immunological and genomic profiles significantly differs between primary and secondary AS, with potential impact on treatment strategies and a role for immunotherapy. Tumor-infiltrating lymphocytes were analyzed using multiplex immunohistochemistry from 79 pAS and 178 sAS. Median cell density was significantly higher in sAS for CD3+ T-cells (p < 0.001), CD8+ cytotoxic T-cells (p = 0.033), CD4+ T-helper cells (p < 0.001) and FoxP3+ T-regulatory cells (p < 0.001). CD20+ B-cell density was comparable (p = 0.417). Comprehensive genomic profiling was performed in 25 pAS and 25 sAS. A (likely) pathogenic mutation was detected in 80% of pAS vs. 88% of sAS (p = 0.702). Amplifications were found in 15% of pAS vs. 84% of sAS (p < 0.001). DNA damage response (DDR) pathway mutations (p = 0.021) and MYC amplifications (p < 0.001) were predominantly seen in sAS. In conclusion we observed a clear and clinical relevant distinction in immune infiltration and genomic profiles between pAS and sAS. The T-cell infiltrated tumor microenvironment and frequent DDR gene mutations, especially in sAS, warrant clinical trials with immunotherapy.
Open AccessImmunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma Subgroups
Angiosarcomas (AS) are extremely rare and aggressive vascular malignancies subdivided in de novo primary AS (pAS) and secondary AS (sAS). We hypothesize that the combination of immunological and genomic profiles significantly differs between primary and secondary AS, with potential impact on treatment strategies and a role for immunotherapy. Tumor-infiltrating lymphocytes were analyzed using multiplex immunohistochemistry from 79 pAS and 178 sAS. Median cell density was significantly higher in sAS for CD3+ T-cells (p < 0.001), CD8+ cytotoxic T-cells (p = 0.033), CD4+ T-helper cells (p < 0.001) and FoxP3+ T-regulatory cells (p < 0.001). CD20+ B-cell density was comparable (p = 0.417). Comprehensive genomic profiling was performed in 25 pAS and 25 sAS. A (likely) pathogenic mutation was detected in 80% of pAS vs. 88% of sAS (p = 0.702). Amplifications were found in 15% of pAS vs. 84% of sAS (p < 0.001). DNA damage response (DDR) pathway mutations (p = 0.021) and MYC amplifications (p < 0.001) were predominantly seen in sAS. In conclusion we observed a clear and clinical relevant distinction in immune infiltration and genomic profiles between pAS and sAS. The T-cell infiltrated tumor microenvironment and frequent DDR gene mutations, especially in sAS, warrant clinical trials with immunotherapy.